Applied Therapeutics/APLT

$7.07

-0.7%
-
1D1W1MYTD1YMAX

About Applied Therapeutics

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of product candidates against validated molecular targets in indications of high unmet medical need. The Company’s molecular target is aldose reductase (AR), an enzyme that converts glucose to sorbitol under oxidative stress conditions. The Company’s product candidates include AT-007, AT-001, and AT-003. Its AT-007 is a central nervous system (CNS) penetrant ARI for the treatment of CNS rare diseases, including Galactosemia, sorbitol dehydrogenase (SORD) deficiency, and PMM2-CDG. AT-001 is an aldose reductase inhibitor (ARI) with exposure and nerve permeability. AT-001 is being developed for the treatment of diabetic cardiomyopathy (DbCM), a fatal fibrosis of the heart. Its AT-003 is an ARI designed to cross through the back of the eye when dosed orally. AT-003 is developed for the treatment of diabetic retinopathy (DR).

Ticker

APLT

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Shoshana Shendelman

Employees

22

Headquarters

New york, United States

APLT Metrics

BasicAdvanced
$549.87M
Market cap
-
P/E ratio
-$1.31
EPS
1.83
Beta
-
Dividend rate

What the Analysts think about APLT

Analyst Ratings

Majority rating from 4 analysts.
Buy

Price Targets

Average projection from 4 analysts.
30.83% upside
High $14.00
Low $4.00
$7.07
Current price
$9.25
Average price target

APLT Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-42.3M
43.39%
Profit margin
0%
-

APLT Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 81.23%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.16
-$0.18
-$0.37
-$0.47
-
Expected
-$0.46
-$0.31
-$0.27
-$0.26
-$0.23
Surprise
-65.39%
-41.27%
39.62%
81.23%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Applied Therapeutics stock

Buy or sell Applied Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing